MedTrace Logo

A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis

NCT02528201 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2015-08-19

No results posted yet for this study

Summary

A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks. This will be used to confirm the results of a prior 6 week trial.

Conditions

Interventions

DRUG

Celecoxib 200 milligrams

Celecoxib 200 milligrams once a day

DRUG

Celecoxib 400 milligrams

Celecoxib 400 milligrams once a day

DRUG

diclofenac 50 milligrams

diclofenac 50 milligrams three times a day

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2004-11-30
Completion
2004-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02528201 on ClinicalTrials.gov